GLX1112 / Glialogix, National Multiple Sclerosis Society - LARVOL DELTA

Glialogix and National Multiple Sclerosis Society enter into collaboration to support development of a new oral therapy for progressive multiple sclerosis (Glialogix Press Release) - "Glialogix...announced that it has entered into a Sponsored Research Agreement with Fast Forward, a nonprofit organization established by the National Multiple Sclerosis (MS) Society to accelerate the development of treatments for MS. Through this agreement, Fast Forward will provide funding to Glialogix for preclinical studies of GLX1112, a first-in-class neuroprotective therapy designed to slow the accumulation of disability in progressive MS."

New molecule • Preclinical • Multiple Sclerosis